Join CEO and Founder of Neurovations Dr. Eric Grigsby and Chief Medical Officer of Setpoint Dr. David Chernoff for an in-depth discussion on the activation of neuroimmune reflexes by Vagus Nerve Stimulation which reduced disease activity in a proof-of-concept study in Rheumatoid Arthritis. Rheumatoid Arthritis is an autoimmune disease that leads to permanent joint destruction and accelerated mortality requiring lifelong immunosuppressive therapies.
Dr. Eric Grigsby, MD, MBA is Chief Executive Officer and Founder of Neurovations. For over three decades, Dr. Grigsby has focused his clinical career on academia and private practice. Today, in addition to busy practices, surgery centers, education divisions and labs, Dr. Grigsby guides research and innovation at Neurovations.
Dr Grigsby has been seminally involved in the majority of the interventional devices and therapies used in the field of pain management. He guides start-ups and industry-leading companies through the innovation, discovery and clinical research process which includes access to sites for clinical investigation in pain and neurologic disease.
The Neurovations Education division holds world-class programs and ACCME accredited conferences in Pain and Neuroscience. Additionally, Neurovations Education helps companies and clinicians develop and learn surgical therapies. Dr. Grigsby’s non-profit foundation, HealthRoots, is committed to community health and innovation for underserved patients and communities.
Originally from Knoxville, Tennessee, Dr. Grigsby is a graduate of Brown University with an undergraduate degree in Biology and Economics. He completed medical school at Boston University School of Medicine and residency training in Anesthesiology and Pain Medicine at the Mayo Clinic in Rochester, Minnesota. He received his Master’s in Business Administration in Health Sector Management from Duke University.
lDavid Chernoff has 25 years of molecular diagnostics and biopharmaceutical experience and has served as a translational medicine consultant to more than 40 biopharma and device companies. He has held chief medical officer posts with a number of venture capital backed diagnostic and therapeutic companies. He was formerly VP of Corp Technology at Elan Pharma and Medical Director at Chiron Corp.